Nabriva Therapeutics, an Austrian biotechnology company developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, has appointed Charles Rowland to the Nabriva Supervisory Board and Steven Gelone to the position of Chief Development Officer and a member of the Management Team.
Rowland has more than 30 years of diversified experience across a number of financial areas. Most recently, he was Vice President and Chief Financial Officer of ViroPharma, until its acquisition by Shire last year.
Prior to joining ViroPharma in 2008, Rowland was Executive Vice President and Chief Financial Officer, as well as the interim Co-Chief Executive, at Endo Pharmaceuticals.
Before this, he held leadership positions at Biovail, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb.
Rowland is also a member of the board of directors and chairs the audit committee of Bind Therapeutics, Aurinia Pharmaceuticals and Vitae Pharmaceuticals.
Steven Gelone has been involved in all stages of drug development and commercialisation for 20 years. Most recently he was Head of Clinical Research and Development at Spark Therapeutics and was Vice President of Development at ViroPharma. Prior roles include leadership positions at GSK, Vicuron Pharmaceuticals and Temple University Schools of Pharmacy and Medicine.
Dr Denise Pollard-Knight, Chairman of the Supervisory Board of Nabriva, said the expertise of the two men would be invaluable as the company accelerates its programmes.
'Charles’ financial expertise, combined with his understanding of the pharmaceutical sector, and Steven’s expertise in drug development and commercialisation will bring further depth to Nabriva. We look forward to working with them,' she said.
